Study at a glance
Do inherited vitamin D receptor differences affect breast cancer cells?
Researchers compared two inherited forms of the vitamin D receptor, a protein that helps cells respond to active vitamin D. They used human breast cancer cells modified in the laboratory to produce a shorter or longer receptor. They then exposed the cells to the active vitamin D hormone.
How did the breast cancer cells respond to active vitamin D?
Cells with the shorter receptor showed a larger reduction in growth than cells with the longer receptor. They also showed a stronger response in a vitamin D-related gene and a larger fall in an oestrogen receptor protein. The shorter vitamin D receptor was more stable in a separate laboratory test. These differences were observed in this particular cell model.
Did the vitamin D receptor form explain every difference between the cells?
The cells were grown from selected individual cells and deliberately modified. Differences between these cell groups, including how much receptor they produced, could also affect their responses. The study did not establish that the receptor form alone explained every difference.
Does this cell study show that vitamin D can treat breast cancer?
The study did not test treatment in people or show that vitamin D supplements prevent or treat breast cancer. It also did not establish that an inherited receptor form determines cancer risk or disease progression. Responses in laboratory cancer cells cannot be assumed to describe effects throughout the body.
Read the full article below ↓This page provides a concise summary of a single verified primary study. For full methodological detail, measurement constraints, and inference boundaries, see the Common VDR Polymorphisms and Functional Implications: Full Evidence Review.
Study identity
Study type: Primary experimental laboratory study using engineered human breast cancer cell lines
Population or system studied: MCF-7 human breast cancer cells, including stable single-cell clones expressing defined VDR FokI variants
Primary exposure or variable: Vitamin D receptor FokI genotype variant (VDRff vs VDRFF) with 1α,25-dihydroxyvitamin D3 exposure
Primary outcome category: Functional cellular response and gene expression response to 1α,25(OH)2D3 under defined receptor-variant conditions
Purpose of the study
The study set out to test whether a common VDR start-codon polymorphism (FokI) is associated with functional differences in vitamin D signalling effects in a controlled cellular system. The key framing move is methodological: rather than infer “functional significance” from population associations, the authors built stable cell-line models that differ in the VDR variant they express, then measured whether those variants show different magnitudes of response to the active vitamin D hormone.
Study overview
Researchers generated stable MCF-7 single-cell clones that either carried a control vector, expressed the longer VDR protein form (VDRff), or expressed the shorter form (VDRFF). Cells were then treated with 1α,25(OH)2D3 and evaluated for growth inhibition and selected molecular readouts that reflect VDR-driven transcriptional response.
Key readouts included the magnitude of growth inhibition after hormone exposure, induction of a canonical vitamin D target gene (CYP24A1 mRNA), and changes in estrogen receptor-α protein expression. The study also assessed VDR protein stability under cycloheximide conditions and used a PCR array approach to compare basal expression patterns of selected genes between the variant-expressing cell lines.
Key findings
Under 1α,25(OH)2D3 treatment, VDRFF-expressing cells showed a larger growth-inhibitory response than VDRff-expressing cells in this model system. In parallel, induction of CYP24A1 mRNA was higher in VDRFF cells than in VDRff cells, consistent with a stronger transcriptional response to the hormone under the conditions tested.
The study also reported larger downregulation of estrogen receptor-α protein expression in VDRFF cells than in VDRff cells. In addition, VDR protein stability was described as greater in the VDRFF-expressing cells in the presence of cycloheximide, supporting the possibility that receptor-variant behaviour differs in ways that can matter for the magnitude of downstream responses in this cellular setting.
What this study shows
In a controlled experimental system where the receptor variant is defined and held constant within stable single-cell clones, the two common FokI-linked VDR protein forms can be associated with measurably different response magnitudes to 1α,25(OH)2D3. The specific outputs tested in this study indicate that, at least in this MCF-7 model, the shorter VDR form (VDRFF) aligned with stronger growth inhibition and stronger induction of a canonical vitamin D target gene than the longer form (VDRff).
It also shows that “functional implications” can be operationalised in multiple ways: not only through a growth endpoint, but through receptor-linked transcriptional outputs (CYP24A1 induction), hormone-linked regulation of a major signalling axis in these cells (estrogen receptor-α protein), and stability-related behaviour that can influence effective signalling over time.
What this study does not show
This study does not establish population-level effects of the FokI polymorphism, because it is not a population study. It does not estimate how these variants behave across tissues in vivo, nor does it quantify how genotype effects might be modified by circulating vitamin D status, endocrine dynamics, or cell-type-specific cofactor availability.
It also does not justify extending these specific effect sizes to clinical outcomes. Even where the authors discuss the implications for “aggressive breast cancer” phenotypes, the data remain bounded to this engineered cellular context and the specific endpoints measured. The study tests response magnitude differences under defined conditions; it does not prove that genotype causes particular clinical trajectories.
Relevant measurement framing: Vitamin D Status vs Vitamin D Effect.
Limitations (high level)
The model uses stable single-cell clones derived from a breast cancer cell line, which improves control but limits generalisability. The system focuses on a specific cellular context with a particular transcriptional environment, and the measured outcomes represent only a subset of possible VDR-mediated behaviours.
Differences in measured response magnitude may reflect multiple factors in addition to the receptor protein variant itself, including clone-specific cellular state, expression level differences, and context-dependent co-regulator interactions. The study provides evidence of variant-associated differences in this system; it does not isolate a single mechanistic cause for those differences.
Interpretation within vitamin D physiology
Within a physiology-first framework, this study is best used to support a bounded claim: receptor-genotype-linked structural differences can matter for signalling output magnitude in at least some cellular contexts. That is a different axis from ligand availability or circulating status, and it helps explain why “vitamin D effect” can vary even when the same ligand is applied under controlled conditions.
To understand the receptor layer that sits above these cellular readouts, see Vitamin D Receptors.
For relevant physiology background, see Vitamin D Receptor Polymorphisms.
Relevant genetics layer: Vitamin D Genetics.
Primary source and publication details
Alimirah F, Peng X, Murillo G, Mehta RG, et al.
Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells
PLOS ONE. 2011.
DOI: 10.1371/journal.pone.0016024
https://pubmed.ncbi.nlm.nih.gov/21283672
Related reading
25-Hydroxyvitamin D3 1α-hydroxylase expression in breast cancer and use of non-1α-hydroxylated vitamin D analogue
In addition, expression of the 25-hydroxyvitamin D3 24-hydroxylase (24-hydroxylase) and the vitamin D receptor (VDR) was investigated.
Original paper ↗Read more →Association between the BsmI Polymorphism in the Vitamin D Receptor Gene and Breast Cancer Risk: Results from a Pakistani Case-Control Study
Here, we investigated the possible contribution of these SNPs to breast cancer risk in Pakistani breast cancer patients and in controls participating in a hospital-based breast cancer case-control study (PAK-BCCC).
Original paper ↗Read more →Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort
The GC rs2282679 minor allele was significantly associated with luminal subtype of the primary tumor compared to Her2+/TN breast cancer (p = 0.007).
Original paper ↗Read more →Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: A potential new therapeutic approach
The aim of the present study was to determine if calcitriol induces ERα expression in ER-negative breast cancer cells, thus restoring antiestrogen responses.
Original paper ↗Read more →Cdx2 Polymorphism Affects the Activities of Vitamin D Receptor in Human Breast Cancer Cell Lines and Human Breast Carcinomas
The objective of this study is to assess the relationship between the Cdx2 VDR polymorphism and the activities of VDR in human breast cancer cell lines and carcinomas breast patients.
Original paper ↗Read more →Circulating vitamin D status and prognosis in colorectal cancer: a systematic review and meta-analysis with exploratory evidence on vitamin D receptor polymorphisms
This study aimed to investigate the association between circulating 25(OH)D levels and CRC prognostic outcomes, with a narrative evaluation of VDR polymorphisms.
Original paper ↗Read more →Functional Significance of Vitamin D Receptor FokI Polymorphism in Human Breast Cancer Cells
In response to 1α,25 (OH)2D3 treatments, cell growth was inhibited by 60% in VDRFF cells compared to 28% in VDRff cells.
Original paper ↗Read more →Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies
In this study, the VDR gene has been evaluated in two epithelial cancers BC and MM.
Original paper ↗Read more →Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial
This study was aimed to assess the impact of vitamin D3 supplementation on the serum concentration of inflammatory markers and antioxidant capacity with regard to VDR polymorphism in the VDR gene in breast cancer women.
Original paper ↗Read more →In vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors
These results provide the bases for further studies aimed at testing EAG1-dual targeting in breast cancer tumors expressing both EAG1 and the vitamin D receptor.
Original paper ↗Read more →Polymorphism of VDR Gene and the Sensitivity of Human Leukemia and Lymphoma Cells to Active Forms of Vitamin D
Therefore, the study aimed to determine the use of an active form of vitamin D3 calcitriol and its analog tacalcitol as an anticancer drug.
Original paper ↗Read more →Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study
The aim was to investigate associations between four previously studied VDR SNPs (Taq1, Tru91, Bsm1, and Fok1) and prognosis in different groups of breast cancer patients.
Original paper ↗Read more →The association of VDR polymorphisms and type 2 diabetes in older people living in community in Santiago de Chile
Several polymorphisms have been associated with obesity and type 2 diabetes in different populations.
Original paper ↗Read more →The ERRα-VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer
Besides estrogen receptor alpha (ERα), estrogen‐related receptor alpha (ERRα) has also been shown to interfere with the VDR pathway, but its role in the antitumor and transactivation activity of calcitriol is completely unknown in breast cancer (BC).
Original paper ↗Read more →Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models
1,25-Dihydroxycholecalciferol, the hormonally active vitamin D3 metabolite, is known to exhibit therapeutic effects against breast cancer, mainly by lowering the expression of estrogen receptors and aromatase activity.
Original paper ↗Read more →Vitamin D May Protect against Breast Cancer through the Regulation of Long Noncoding RNAs by VDR Signaling
Dietary vitamin D3 has attracted wide interest as a natural compound for breast cancer prevention and therapy, supported by in vitro and animal studies.
Original paper ↗Read more →Vitamin D Receptor Cdx-2 Polymorphism and Premenopausal Breast Cancer Risk in Southern Pakistani Patients
Pearson chi square test was used to assess the association between VDR-Cdx2 genotype and breast cancer while genotype distribution in controls was evaluated by Hardy-Weinberg equilibrium (HWE).
Original paper ↗Read more →Vitamin D receptor expression in invasive breast tumors and breast cancer survival
Vitamin D exerts its functions through the vitamin D receptor (VDR), and the aim of the current study was to investigate if the expression of VDR in invasive breast tumors is associated with breast cancer prognosis.
Original paper ↗Read more →Vitamin D receptor FokI polymorphism and the risks of colorectal cancer, inflammatory bowel disease, and colorectal adenoma
In the present case-control study, compared to the F allele, the f allele seemed to be associated with lower risks of colon cancer and advanced colorectal cancer.
Original paper ↗Read more →Vitamin D receptor gene polymorphism in oral cancer as a function of tobacco consumption: an evidence based systematic review and meta-analysis
The aim was to evaluate the correlation (if any) between Vitamin D receptor (VDR) gene variation with tobacco-related oral cancer by analyzing the existing evidence.
Original paper ↗Read more →Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
Effect modification by serum 25-hydroxyvitamin D (25 [OH]D), the biomarker for vitamin D status in humans, has rarely been examined.
Original paper ↗Read more →Original sources
Functional Significance of Vitamin D Receptor FokI Polymorphism in Human Breast Cancer Cells
In response to 1α,25 (OH)2D3 treatments, cell growth was inhibited by 60% in VDRFF cells compared to 28% in VDRff cells.
Publication details
https://pubmed.ncbi.nlm.nih.gov/21283672